Jump to content

DHAP (chemotherapy)

From Wikipedia, the free encyclopedia
DHAP
SpecialtyOncology

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. (D)examethasone, a glucocorticoid hormone
  3. (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
  4. (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.

Dosing regimen

[edit]
Drug Dose Mode Days
Rituximab 375 mg/m2 IV infusion Day 0
Dexamethasone 40 mg PO qd Days 1-4
High-dose Ara-C - cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 2, every 12 hours
Platinol (cisplatin) 100 mg/m2 IV infusion over 24 hrs Day 1

References

[edit]
  1. ^ Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=DHAP_(chemotherapy)&oldid=1236566510"